Clinical Trial Detail

NCT ID NCT02080078
Title A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors AHS Cancer Control Alberta, Cross Cancer Institute
Indications

lung non-small cell carcinoma

Advanced Solid Tumor

Therapies

Erlotinib + Theophylline

Age Groups: adult

No variant requirements are available.